MVT 5873

Drug Profile

MVT 5873

Alternative Names: 5B1-(sLeA)-therapeutic; Anti-CA19.9 antibody; anti-sialyl Lewisa antibody; HuMab-5B1; HuMab-5B1 antibody; MVT-5873

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center; Sarah Cannon Research Institute
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CA-19-9 antigen inhibitors; GD2 ganglioside modulators; Tumour-associated carbohydrate antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer; Colorectal cancer; Pancreatic cancer
  • Preclinical Small cell lung cancer

Most Recent Events

  • 22 Aug 2017 MabVax completes the phase I trial in Pancreatic cancer and Cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA
  • 02 Jun 2017 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Pancreatic cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Jun 2017 Phase-I clinical trials in Cancer and Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT03118349)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top